This framework demonstrates cross-disorder genetic analysis for schizophrenia and major depressive disorder, revealing shared risk factors and high prediction accuracy.
Abstract This comprehensive study presents an integrated metaheuristic-deep learning framework for cross-disorder analysis of schizophrenia (SCZ) and major depressive disorder (MDD) using genome-wide association studies (GWAS) data. Our methodology combines: (1) a multi-objective genetic algorithm with biological constraints for SNP selection, (2) a dual-task convolutional neural network for joint disorder prediction, and (3) multi-modal biological validation. The optimized model achieves 93.7% accuracy for SCZ (AUC=0.96) and 90.2% for MDD (AUC=0.93) with 300 training epochs, while identifying 1,842 shared risk SNPs showing significant enrichment in calcium signaling pathways (\(p=3.2 × 10⁻¹⁴\)). These findings establish a scalable framework for cross-disorder genetic analysis in psychiatry with detailed mathematical formulations of optimization objectives and network architecture specifications.
No takes yet. Share an insight, caveat, or question.
Miloudi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: